Credit: mannKind. Furoscix ReadyFlow offers a rapid, outpatient alternative for acute fluid overload management in heart failure and chronic kidney disease. Furoscix ReadyFlow demonstrated a ...

The oral RAS(ON) multi-selective inhibitor nearly doubled overall survival compared with investigator’s choice chemotherapy in the phase 3 RASolute 302 trial.

Retatrutide 12mg achieved up to 22.6% (55.8 lbs) mean weight loss at week 80, alongside marked improvements in ...

Cancer progression within 36 months of combination therapy identified patients with overall survival of less than 2 years.

Lundbeck’s investigational oral orexin 2 receptor agonist gains Fast Track status, aiming to address underlying pathophysiology in patients with narcolepsy.

Delaying JAK inhibitor initiation yielded higher early antibody responses; earlier initiation linked to earlier improvement in arthritis.

Jideytro is FDA-approved for adult patients with locally advanced or metastatic ROS1-positive NSCLC who received prior ROS1 TKI therapy.

In the CALIBRATE trial, 76% of encaleret-treated patients normalized both blood and urine calcium at week 24 vs 4% on standard of care, while 91% achieved intact PTH restoration.

One in about 7300 individuals in the general population have PMS, a rare genetic condition that causes medical, intellectual, and behavioral challenges.

For patients aged 4 to 66 years with acquired hypothalamic obesity, setmelanotide leads to significantly greater reductions ...

Phase 1/2 GOBLET trial results demonstrated a 30% ORR (median DOR: 15.5 months) in 2L+ SCAC and an ~29% ORR (median DOR: ~17 months) in 3L SCAC. The Food and Drug Administration (FDA) has granted Fast ...

TG-C failed to demonstrate statistically significant improvements over placebo in pain (VAS) or function (WOMAC) at 12 months. Topline data were announced from the phase 3 ACTiVION-II trial evaluating ...